Clinical Trials on Hemostasis in China

Total 413 results

Fuling Zhou

Recruiting

Double Filtration Plasmapheresis Combined With Chemotherapy

Multiple Myeloma

China
Xinqiao Hospital of Chongqing
Carbiogene Therapeutics Co. Ltd.

Recruiting

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Multiple Myeloma

China
Shanghai Simnova Biotechnology Co.,Ltd.

Active, not recruiting

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Unknown

PDD vs PAD to Treat Initially Diagnosed MM

Multiple Myeloma

China
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
First Affiliated Hospital of Zhejiang University

Unknown

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Multiple Myeloma

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Multiple Myeloma

China
Jinling Hospital, China

Unknown

Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma (CTd)

Multiple Myeloma

China
Yongping Zhai

Unknown

Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

Multiple Myeloma

China
Wuhan University
Tongji Hospital

Unknown

The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy (HLJDT-2016)

Multiple Myeloma

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Yao Liu

Recruiting

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Lymphoma | Multiple Myeloma

China
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
Keymed Biosciences Co.Ltd

Recruiting

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Weijun Fu
Nanjing Legend Biotech Co.

Active, not recruiting

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Beijing Chao Yang Hospital
Peking University People's Hospital

Unknown

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Extramedullary Plasmacytoma

China
Institute of Hematology & Blood Diseases Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Not yet recruiting

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Zhujiang Hospital
The Third Affiliated Hospital of Southern Medical University; Sun Yat-Sen Memorial... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)

Relapsed/Refractory Multiple Myeloma(MM)

China
The First Affiliated Hospital of Soochow University

Recruiting

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY008 PET Imaging in Patients

Multiple Myeloma

China
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Multiple Myeloma

China
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; Jiangsu Province... and other collaborators

Recruiting

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Active, not recruiting

Cohort Construction and Prognostic Model Construction for Multiple Myeloma

Multiple Myeloma

China
Zhongnan Hospital

Completed

Plasma-free Replacement in Patients With Multiple Myeloma

Multiple Myeloma

China
Second Military Medical University
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Unknown

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Liao Aijun

Recruiting

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Bendamustine

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Relapsed or Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
MethylGene Tech Co., Ltd. China

Recruiting

ctDNA Methylation Sequencing for Myeloma

Multiple Myeloma

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Relapsed or Refractory Multiple Myeloma

China
Xinhua Hospital, Shanghai Jiao Tong University...
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Multiple Myeloma | Plasma Cell Leukemia

China
Tianjin Medical University General Hospital

Recruiting

Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors (GCTHCM)

Neoplasm Metastasis | Venous Thromboembolism | Blood Coagulation Disorder With Shortened Coagulation Time (Disorder)

China
The First Affiliated Hospital of Dalian Medical...
Beijing Friendship Hospital

Unknown

Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.

Aging | Acute Coronary Syndrome | Percutaneous Coronary Intervention | Anticoagulants and Bleeding Disorders

China
Clinical Service, China
307 Hospital of PLA; Chinese PLA General Hospital; Peking University Third Hospital and other collaborators

Unknown

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia (Bortezomib)

Multiple Myeloma | Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Multiple Myeloma

China
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

Multiple Myeloma in Relapse

China
Second Affiliated Hospital of Soochow University
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

Relapse Multiple Myeloma

China

Clinical Trials on Hemostasis in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations